» Portus, especially Dr Jonathan Turner, provided us with excellent support when it came to creating our business plan, deciding on the strategic alignment of our business and initiating financing rounds. We profited from Dr. Turner’s profound knowledge in R&D, but also from his experience with business development in drug companies with global operations. Besides, Dr Turner acquired expert know-how as a managing director of biotech firms, and he has an extensive network of pharmaceutical companies and investors – all of which is invaluable for epinamics GmbH, be it during negotiations with potential partners, or for business development. «
Portus’ expertise reaches from product acquisition and divestment to strategic collaborations in life sciences and medtech industries. Here too, we can accompany our clients at all stages from contact to deal.
Using widely acknowledged methods of project valuation, we will determine the value of your project.
As part of the portfolio management we analyze your current portfolio and optimizing opportunites.
We use the market and competitive analysis to create a comprehensive overview of the market situation and the current competitors. Based on these analyses we discuss the further strategies.
In addition to the identification of potential collaboration and licensing partners or potential buyers, we will accompany you through the negotiation process.
A biotech company had developed a novel technology platform, with broad potential applications in healthcare and consumer markets, but lying outside the strategic focus of the initiator.
A strategic analysis of the dvelopment and commercialization scenarios for the platform was completed, and on this basis the creation of a spin-out company, which fully acquired the asset, was recommended. Invour advisory capacity we structured the spin-out and brought the right investors/acquirers to the table. After foundation, we continued to advise and operationally support the new company in project management, business development and in planning and execution of a cooperation strategy.
Through our advice and support, the initiator company was able to effectively monetize a non-strategic asset. In the spinout a focus was set on the therapeutic applications of the technology, while in parallel via business development activities the medtech, consumer and industrial applications were successfully partnered (in EU and USA). After successful further pharmaceutical development by the spin out, we sought international partners for a therapeutic application, and negotiated a term sheet for a two digit million dollar deal with an international player.